Breaking News

UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients

December 31, 2023
Anna Yeo/STAT

UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients

Health insurance giant UnitedHealth Group used secret rules to restrict access to rehabilitation care requested by specific groups of seriously ill patients, including those who lived in nursing homes or suffered from cognitive impairment, according to internal documents obtained by STAT. Read more.

By Bob Herman and Casey Ross



Marian F. Moratinos for STAT

What comes after Wegovy? The quest to eradicate obesity

Though pharma companies are ushering in an obesity treatment revolution, little is being done to address why rates of obesity have soared and continue to tick up, the result of a thicket of biological, social, economic, and policy drivers. So now, to tackle those challenges, the same companies are jumping into the next phase of the revolution: a mission to eliminate obesity altogether. Read more.

By Elaine Chen, Andrew Joseph, and Damian Garde


Justin Sullivan/Getty Images

People hate drug ads on TV. Here's the 4 issues they complain about most

It's time to take stock of the year that was in health and science: the meteoric rise of weight loss drugs, the approval of the first CRISPR-based therapy, the continuing effects of abortion access restrictions after the Dobbs decision, and much more. This is our annual list of stories that STAT staffers loved, and wish that they had written. Read more.

By STAT staff


More great reads from STAT this week


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Weekend Reads? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments